---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014272"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:45:57.932188+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics announces Fast Track and Breakthrough Therapy designations for SAB-176 anti-influenza candidate

## Summary
- Fast Track Designation granted by FDA for SAB-176, an anti-influenza polyclonal antibody therapy.
- Breakthrough Therapy Designation also received for SAB-176, potentially expediting development and review.
- Company published an updated corporate strategy presentation on its website discussing these designations and platform.
- SAB-176 targets influenza; regulatory milestones may accelerate clinical timeline.

## SEC filing metadata
- accession: 0001437749-23-014272
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923014272/0001437749-23-014272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923014272/sabs20230508_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014272
- JSON: https://secwatch.observer/filing/0001437749-23-014272.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.